Curaleaf Holdings reported a modest revenue increase to $320 million in Q3 2025, driven by stable domestic performance and strong international growth, while achieving enhanced margins and maintaining a healthy cash position.

• Revenue grew 2% sequentially, with international segment up 12% sequentially and 56% year-over-year.
• Adjusted gross margins improved to 50%, reflecting a 115 basis point increase.
• Achieved $69 million in adjusted EBITDA, with a 22% margin despite headwinds from international operations.
• Strong cultivation improvements led to average flower potency exceeding 30% for the first time.
• Closed a $100 million revolving credit line to improve financial flexibility and reduce debt obligations.